Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
Phase 1
30
about 2.6 years
18+
22 sites in CA, FL, IL +7
What this study is about
This trial is testing a treatment with ZEN003694 added to usual chemotherapy in patients whose cancer has spread or cannot be removed by surgery. The goal is to determine the safety and best dose of ZEN003694 when used together with capecitabine.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take BET Bromodomain Inhibitor ZEN-3694
- 2.Take Capecitabine
- 3.Undergo Biopsy Procedure
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
capecitabine
oral (Oral Tablet)
Primary: Incidence of adverse events, Maximum tolerated dose (MTD), Recommended phase 2 dose (RP2D)
Secondary: Objective response rate (ORR), Pharmacodynamics (PD) of ZEN003694 (ZEN-3694) in combination with capecitabine, Pharmacokinetics (PK) of ZEN003694 (ZEN-3694) in combination with capecitabine, Progression free survival (PFS)
biopsy, diagnostic, imaging
Oncology